Partner David Simon and Special Counsel John Turlais contributed an article to Wisconsin Law Journal, “Using Tech to Avoid Trouble with Foreign Corrupt Practices Act,” on August 25, 2016. The article discussed FOLEY Global Risk Solutions (GRS), a cloud-based technology solution that provides middle-market companies with international sales and operations an effective compliance program they can implement on their own.
Simon and Turlais described the need and impetus for designing GRS, “The usual system of providing advice on an hourly basis just didn’t work for many [middle-market companies with international sales and operations] companies. It produced high and unpredictable fees and resulted in advice and recommendations rather than a functioning compliance program … We knew we had to rely on technology to fulfill our promise of providing a real anti-bribery compliance program that would be designed to meet regulators’ expectations and that could be offered at a reasonable fixed price.”
Simon and Turlais described the need and impetus for designing GRS, “The usual system of providing advice on an hourly basis just didn’t work for many [middle-market companies with international sales and operations] companies. It produced high and unpredictable fees and resulted in advice and recommendations rather than a functioning compliance program … We knew we had to rely on technology to fulfill our promise of providing a real anti-bribery compliance program that would be designed to meet regulators’ expectations and that could be offered at a reasonable fixed price.”
Author(s)
Related Insights
July 23, 2025
Foley Viewpoints
The One Big Beautiful Bill and Workplace Immigration Enforcement
The “One Big Beautiful Bill Act,” signed into law by President Trump on July 4, 2025, will fund government efforts to continue to…
July 23, 2025
Health Care Law Today
Update: CMS Extends Skilled Nursing Facilities’ Medicare Revalidation Deadline
On April 17, 2025, the Centers for Medicare and Medicaid Services (CMS) announced another extension of the deadline by which skilled nursing facilities (SNFs) must revalidate their Medicare enrollments.
July 22, 2025
Health Care Law Today
GLP-1 Receptor Agonists: Clinical Trial Considerations
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®).